Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Julphar
Daiichi Sankyo
Chinese Patent Office
Cantor Fitzgerald
UBS
Dow
Medtronic

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,974,590

« Back to Dashboard

Which drugs does patent 6,974,590 protect, and when does it expire?

Patent 6,974,590 protects FENTORA and is included in one NDA.

This patent has thirty-two patent family members in twelve countries.
Summary for Patent: 6,974,590
Title: Sublingual buccal effervescent
Abstract:A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Inventor(s): Pather; Sathasivan Indiran (Plymouth, MN), Khankari; Rajendra K. (Maple Grove, MN), Eichman; Jonathan D. (Ann Arbor, MI), Robinson; Joseph R. (Madison, WI), Hontz; John (Plymouth, MN)
Assignee: Cima Labs Inc. (Minneapolis, MN)
Application Number:10/080,016
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,974,590
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,974,590

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-001 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-002 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-006 Mar 2, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-003 Sep 25, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,974,590

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,509,036 Effervescent drug delivery system for oral administration ➤ Sign Up
6,641,838 Effervescent drug delivery system for oral administration ➤ Sign Up
6,764,696 Effervescent drug delivery system for oral administration ➤ Sign Up
6,200,604 Sublingual buccal effervescent ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Federal Trade Commission
Healthtrust
AstraZeneca
Julphar
McKesson
Chinese Patent Office
Medtronic
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.